InvestorsHub Logo
Post# of 252864
Next 10
Followers 45
Posts 4635
Boards Moderated 0
Alias Born 07/19/2006

Re: iwfal post# 114059

Friday, 02/04/2011 1:16:29 PM

Friday, February 04, 2011 1:16:29 PM

Post# of 252864

It has been mentioned on this board that the reason for the difference between the script market share (over 50% at this point) and the $ market share is the unit size being sold by Sandox is smaller on average than being sold by SNY



i believe this was DD's assertion since SNY was careful to say they had 67% market share by volume on their Q3 cc. it is known that sandoz didn't have the vial approved at launch, and the higher dose prefilled syringes tend to be used in the hospital more than in outpt setting, so this makes sense. lastly SNY admits the hospital sector was not hit as hard as retail


Do we have data to confirm that all the major GPOs actually have contracts with Sandoz? If not then the market share of Sandoz in hospitals could be substantially different than in scripts



don't know and i would be curious what bill has to say, but as above the market share for sandoz is lower in hospitals per SNY. now this may have nothing to do with GPO contracts since margins in retail are a bit higher so sandoz probably focused on that market more since they were supply constrained

) How different is the Sandoz price to a GPO than the Sandoz price to a retailer? 30%? 50%? 2x?



again i don't know but i can make an educated guess that since most retailers now are either part of large networks or the insurers use PBMs they can negotiate prices that are not all that different from GPOs. i seem to recall somewhere reading that retail accounts for about 30% of the market by volume and 40% by dollars, so the pricing is a bit better but not by all that much (and part of that is the fact the lower dose prefilled syringes may be more expensive per unit/mg regardless of hospital vs retail, and hospitals tend to use more of the larger doses)

edit: i did not see DD's post on the retail vs GPO pricing when posting, but i would add that part of this differential may be due to the differences between size and pricing of syringes as noted above, and not due to true pricing disparity between identical product (i.e. same dose syringes)
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.